Please ensure Javascript is enabled for purposes of website accessibility

Novavax to Start Human Clinical Trials for Its Potential Coronavirus Vaccine in May

By Prosper Junior Bakiny – Apr 8, 2020 at 4:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company’s investigational vaccine for SARS-CoV-2 looked promising in preclinical studies.

Novavax (NVAX 2.20%) has been plowing through the early stages of the development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373, and recently announced that it plans to start human clinical trials in mid-May. Previously, it had been less specific, stating that it planned to initiate clinical trials in "late spring."

Novavax has been assessing various vaccine candidates in animal models, and reports that NVX-CoV2373 demonstrated high immunogenicity -- the ability to trigger the body's immune response -- in preclinical trials. 

Novavax also said that in preclinical studies, NVX-CoV2373 was able to generate effective antibodies against SARS-CoV-2, the coronavirus that causes COVID-19. According to Matthew Frieman, an associate professor at the University of Maryland School of Medicine, the results of these preclinical studies provide "strong evidence that the vaccine created by Novavax has the potential to be highly immunogenic in humans which could lead to protection from COVID-19 and helping to control the spread of this disease."

Hand filling a syringe with liquid from a glass vial.

Image Source: Getty Images.

Even moving at this rapid pace, Novavax still trails several biotech companies in the race to develop a vaccine for SARS-CoV-2. On March 6, Inovio Pharmaceuticals (INO -0.29%) initiated a phase 1 clinical trial for its investigational SARS-CoV-2 vaccine, INO-4800. This trial will involve up to 40 healthy adult volunteers who will each receive two doses of INO-4800 four weeks apart. As it is a phase 1 trial, it will test INO-4800's safety and immunogenicity, but not its efficacy. 

Moderna (MRNA 2.32%) also has already kicked off a phase 1 clinical trial for its potential vaccine for SARS-CoV-2. This trial -- which is being led by the National Institutes of Health -- will involve 45 healthy adult volunteers and will test the vaccine's safety, immunogenicity, and the dosages that generate expected side effects.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$18.60 (2.20%) $0.40
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.72 (-0.29%) $0.01
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$120.99 (2.32%) $2.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.